Study finds ADT for prostate cancer raises Alzheimer's risk by increasing amyloid plaques and blood-brain barrier permeability.

A study from Augusta University suggests that standard hormone therapy treatment for prostate cancer, known as Androgen Deprivation Therapy (ADT), may increase the risk of Alzheimer's disease in men with the cancer. ADT reduces testosterone, but also removes androgens, key regulators of amyloid metabolism, leading to more amyloid left to form plaques - a hallmark of Alzheimer's. The study found that ADT treatment makes the blood-brain barrier more permeable, leading to more inflammation and damage. However, a combination of ADT and natalizumab, a drug used to treat multiple sclerosis and Crohn's disease, reduced inflammation and improved cognitive function in animal models.

August 29, 2024
42 Articles